利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

344 条记录 (耗时 0.021 秒)

    ANTIBODY AGAINST PROTEIN TYROSINE PHOSPHATASE INTRACELLULAR DOMAINS
    94.
    发明公开
    ANTIBODY AGAINST PROTEIN TYROSINE PHOSPHATASE INTRACELLULAR DOMAINS 有权
    抗生素GEGENINTRAZELLULÄREDOMENNER DER蛋白酪蛋白磷酸酯酶

    公开(公告)号：EP1097944A1

    公开(公告)日：2001-05-09

    申请号：EP99928210.6

    申请日：1999-07-06

    申请人： FUSO PHARMACEUTICAL INDUSTRIES LTD.

    发明人： Yamamoto, Hiroshi ,  Tsujikawa, Kazutake ,  Uchino, Yukiko

    IPC分类号： C07K16/18 ,  C12N5/20 ,  C12P21/08 ,  G01N33/53 ,  G01N33/577 ,  C12N15/06

    CPC分类号： C07K16/40 ,  G01N33/573 ,  G01N2333/916

    摘要： Antibodies to intracellular domains of two or more kinds of protein tyrosine phosphatases, methods for generation thereof and cells producing these antibodies are disclosed. The antibody of the present invention may have specificity to intracellular domains of phosphatase subunits of both of LAR and CD45, and may be useful for analysis and quantitative determination of PTPs, identification and detection of novel PTPs, and for obtaining novel phosphatases by cloning and the like, as well as for developing useful diagnostic methods of insulin resistance and NIDDM, for prophylaxis and diagnosis of various disease states of syndrome X that is based on insulin resistance, and for prophylaxis and diagnosis of onsets of arteriosclerosis and cardiac diseases.

    摘要翻译： 公开了两种或更多种蛋白质酪氨酸磷酸酶的细胞内结构域的抗体，其产生方法和产生这些抗体的细胞。 本发明的抗体可能对LAR和CD45两者的磷酸酶亚基的细胞内结构域具有特异性，可用于PTP的分析和定量测定，新型PTP的鉴定和检测，以及通过克隆得到新的磷酸酶 以及用于开发胰岛素抵抗和NIDDM的有用的诊断方法，用于预防和诊断基于胰岛素抵抗的综合征X的各种疾病状态，以及用于预防和诊断动脉硬化和心脏病的发作。

    Method to identify compounds which modulate FRA-1 expression
    95.
    发明公开
    Method to identify compounds which modulate FRA-1 expression 审中-公开
    Verfahren zum Nachweis von Verbindungen zur Modulation FRA-1 Expression

    公开(公告)号：EP1094317A1

    公开(公告)日：2001-04-25

    申请号：EP99118773.3

    申请日：1999-09-23

    申请人： Boehringer Ingelheim International GmbH

    发明人： The designation of the inventor has not yet been filed

    IPC分类号： G01N33/68 ,  A01K67/027 ,  C12N15/06

    CPC分类号： C07K14/4702 ,  A01K2217/05 ,  G01N33/6872 ,  G01N33/6893

    摘要： In a screening method for identifying a substance for the treatment of bone disorders that are associated with reduced bone mass, the substance is tested for its ability to upregulate the expression of Fra-1 or to modulate the expression of a Fra-1 target gene in osteoblasts, said upregulation or modulation resulting in an increased bone formation in vivo. The identified osteoinductive compounds and DNA molecules encoding biologically active Fra-1 molecules can be used for the therapy of bone disorders characterized by a circumscribed or systemic reduction of bone mass.

    摘要翻译： 在用于鉴定用于治疗与骨质量减少相关的骨病症的物质的筛选方法中，测试该物质的上调Fra-1表达的能力或调节Fra-1靶基因的表达 成骨细胞，所述上调或调节导致体内骨形成增加。 所鉴定的骨诱导化合物和编码生物活性的Fra-1分子的DNA分子可用于治疗特征在于骨量限制或全身减少的骨质疏松症。

    INSECTICIDAL GENE AND PEPTIDE
    96.
    发明公开
    INSECTICIDAL GENE AND PEPTIDE 失效
    杀虫GEN和肽

    公开(公告)号：EP1015581A1

    公开(公告)日：2000-07-05

    申请号：EP98902118.3

    申请日：1998-02-02

    申请人： BTG INTERNATIONAL LIMITED

    发明人： SHAW, Christopher

    IPC分类号： C12N15/12 ,  C12N15/06 ,  C07K7/06 ,  C07K7/08 ,  A01N37/44 ,  A61K39/00

    CPC分类号： C07K14/463 ,  A01K2217/05 ,  A01N63/02 ,  A61K39/00 ,  C07K7/06

    摘要： The present invention relates to FMRF amide type peptides and their non-amidated precursors, to recombinant nucleic acids encoding for such peptides, to the use of these nucleic acids, in forms substantially isolated from other nucleic acid or when incorporated into vectors, to transform organisms in order to render them capable of producing these peptides, to the use of such peptides, nucleic acid and vectors as pesticidal agents, eg. insecticidal, acaricidal and helminthecidal agents and to compositions comprising one or more of these. A peptide or salt thereof comprising an amino acid sequence Pro-Pro-(Xaa1)n-Phe-Xaa2-Arg-Xaa3 or a conservatively substituted analogue thereof, wherein the N terminal of said peptide may be free amino or protected amino and the C-terminal of said peptide, which is the C-terminal -Xaa3 of the above sequence, may consist of that residue with a free carboxylic acid group or with an amidated carboxyl of the formula CONR1R2 wherein R?1 and R2¿ are independently selected form hydrogen, alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl and aminoalkyl or together with the nitrogen to which they are attached form a C¿3-8? heterocyclic ring; wherein Xaa?1¿ is any amino acid, which is independently selected at each repeat n, and n is an integer from 0 to 10 and Xaa2 is Met, Val, Ile, Leu, Nle or Phe or a conservatively substituted analogue thereof and Xaa3 is Phe, Asp or Glu, provided that when the peptide is Ile-Pro-Pro-Gln-Phe-Met-Arg-Phe it is not combined with skin of the frog Hylambates (Kassina maculata) is specifically claimed as are nucleic acids encoding therefor.

    ANTIANNEXIN-V MONOCLONAL ANTIBODY, PROCESS FOR PRODUCING THE SAME, AND USE THEROF
    97.
    发明公开
    ANTIANNEXIN-V MONOCLONAL ANTIBODY, PROCESS FOR PRODUCING THE SAME, AND USE THEROF 失效
    单克隆抗体ANTIANNEXIN-V，方法进行生产和及其用途

    公开(公告)号：EP0741144A4

    公开(公告)日：2000-05-24

    申请号：EP95936774

    申请日：1995-11-10

    申请人： INT REAGENTS CORP ,  KANEKO NOBORU

    发明人： KANEKO NOBORU ,  MATSUDA RYUKO ,  KAJITA TADAHIRO ,  OHTA YOHSUKE

    IPC分类号： C07K16/18 ,  C12N15/06 ,  C12P21/08 ,  C12N5/20 ,  G01N33/577

    CPC分类号： C07K16/18 ,  G01N2333/4718

    摘要： An antiannexin-V monoclonal antibody is produced from a hybridoma cell line that is prepared by using a human annexin V alone or together with a canine annexin V, has a binding specificity for the antigenic determinant site of annexin V, an antigenic protein, and produces an antiannexin-V monoclonal antibody belonging to immunoglobulin G. The antiannexin-V monoclonal antibody thus produced is used to diagnose myocardial infarct and angina pectoris, and the first and second antiannexin-V monoclonal antibodies produced from the respective hybridoma cell lines are used to diagnose myocardial infarct and/or angina pectoris by quantifying the human annexin V contained in specimens. The quantifying method comprises effecting an antigen-antibody reaction between the human annexin V and the first antiannexin-V monoclonal antibody to form a human annexin V antigen-antiannexin-V monoclonal antibody complex, binding a labeled antiannexin-V polyclonal antibody or the second monoclonal antibody to the annexin V antigen moiety of the formed antigen-antibody complex to form a labeled conjugate between the antigen-antibody complex and the polyclonal or second monoclonal antibody, and quantifying the labeled conjugate thus formed.